Literature DB >> 17898111

Macrocytosis due to treatment with sunitinib.

Bertrand Billemont, Hassane Izzedine, Olivier Rixe.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17898111     DOI: 10.1056/NEJMc071867

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  The risk for anemia with targeted therapies for solid tumors.

Authors:  Sandro Barni; Mary Cabiddu; Paolo Guarneri; Veronica Lonati; Fausto Petrelli
Journal:  Oncologist       Date:  2012-04-24

2.  A Case of Cobalamin Deficiency and Macrocytic Anemia Secondary to Sunitinib.

Authors:  Jarred P Reed; Joan Chung; Natasha Banerjee
Journal:  Cureus       Date:  2019-03-25

3.  Sunitinib causes macrocytosis in patients with advanced renal cell carcinoma.

Authors:  J Price; R Shaarbaf; L Wood
Journal:  Curr Oncol       Date:  2010-04       Impact factor: 3.677

4.  Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients.

Authors:  Michal Rihacek; Iveta Selingerova; Ivo Kocak; Ilona Kocakova; Eva Rihackova; Dalibor Valik; Jaroslav Sterba
Journal:  Curr Oncol       Date:  2022-06-07       Impact factor: 3.109

5.  Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma.

Authors:  Jakub Kucharz; Agnieszka Giza; Paulina Dumnicka; Marek Kuzniewski; Beata Kusnierz-Cabala; Pawel Bryniarski; Roma Herman; Aneta Lidia Zygulska; Krzysztof Krzemieniecki
Journal:  Med Oncol       Date:  2016-08-30       Impact factor: 3.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.